Published date: 2 November 2021

Last edited date: 3 February 2022

Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.


Approach to market date: 8 February 2022

Contract summary

Industry

  • Blood products - 33141510

  • Plasma extracts - 33141520

  • Pharmaceutical products - 33600000

Location of contract

United Kingdom, Isle of Man, Channel Islands

Value of contract

£74,500,000

Procurement reference

CM/PHS/19/5583.

Published date

2 November 2021

Approach to market date

8 February 2022

Contract start date

1 July 2022

Contract end date

31 December 2023

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

National Framework Agreement for the supply of products for the management of Hereditary Angioedema
Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

More information

Spend profile

This table displays the spend profile of the notice
Financial year Budget
2022/2023 £37,250,000
2023/2024 £37,250,000

About the buyer

Contact name

Karen Bell

Address

Rutland House
Runcorn
WA7 2ES
England

Telephone

01928755245

Email

karen.bell7@nhs.net